Title
Category
Credits
Event date
Cost
  • Disease management
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
$0.00
This activity will review the symptoms and signs of SM, provide an overview of new and current therapies and identify SM guideline updates. The value of an interdisciplinary team–based approach along the continuum of care for affected individuals will also be discussed as a definitive step toward optimizing outcomes. 
  • Disease management
  • Vision
  • 1.00 Attendance - General Attendance
  • 1.00 COPE - Optometrists
$0.00
Ocular Anterior Surface Disease or dry eye syndrome affects nearly 16 million Americans and can be a common and chronic problem for adults, especially for those of advanced age, causing symptoms that interfere with eye comfort, function and quality of life. Competent evaluation to determine the etiology of dry eye syndrome is necessary for successful symptom management as therapeutic regimens must be specific to the underlying causes to be effective. This activity will examine the multiple parts of eye anatomy, the dysfunction of which may contribute to dry eye syndrome, including the tear film, ocular anterior surface and Meibomian gland, and identify complications that can result when dry eye is left untreated. Importantly, a thorough review of optimal treatment regimens will be provided, as well as updates on newer and emerging targeted treatments, with a focus on providing relief and preventing further damage to the eye.
  • Disease management
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
This activity will provide participants with insight into newer approaches that effectively integrate standard interventions into management plans tailored to the individual’s particular symptoms, review the value of pulmonary rehabilitation, and outline the effective evaluation of therapeutic responses.
  • Infectious diseases
  • 0.50 ACPE - Pharmacists
  • 0.50 ACPE - Pharmacy Technicians
  • 0.50 AMA - Physicians
  • 0.50 ANCC - Nurses
  • 0.50 APA - Psychologists
  • 0.50 Attendance - General Attendance
  • 0.50 ASWB - Social Workers
$0.00
This activity will provide participants with the latest science on monkeypox, describing the spectrum of associated symptoms and signs, virulence, and common routes of transmission. Discussion will also focus on the factors driving this outbreak, approaches to prevention and management, and an overview of the impact of this disease globally and in comparison with the current COVID-19 public health emergency.
  • Disease management
  • Vision
  • 1.00 Attendance - General Attendance
  • 1.00 COPE - Optometrists
$0.00
Diabetes can cause potentially irreparable eye damage and poor vision over time. This activity will review the role of optometrists in the areas of prevention, co-management and rehabilitation for individuals with diabetes. It will focus on how to conduct a diabetes risk assessment, ongoing care of individuals with known diabetes and collaboration among members of the interprofessional health care team for optimal outcomes. Key strategies for vision rehabilitation will also be addressed.
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
This activity will discuss The Strategies to Reduce Injuries and Develop Confidence in Elders (STRIDE) trial, which aims to evaluate the effectiveness of evidence-based strategies to reduce serious fall-related injuries,. In addition, faculty will identify risk factors that contribute to falls in the older adult as well as for individuals in SNFs, and provide interventions to reduce the risk of falls. The importance of a multidisciplinary approach in fall management will also be explored.
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This session examines the cost of development and growth of these pharmaceuticals and details the specific role that specialty pharmacy plays in making these products accessible. The high costs of therapies and patient and medication management are also discussed along with the role and value of drug benefit programs.
  • Disease management
  • Wellness
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity will highlight new updates in our understanding of how diabesity develops and describe the negative physiologic effects of this disease on multiple body systems, notably the cardiovascular and renal systems. Optimal treatments for diabesity will be identified, along with an overview of the health burden of diabesity related to long-term complications and reduced function, quality of life and life expectancy. 
  • Disease management
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
This activity will discuss CCTA as a new trend in cardiology imaging and its role in providing a comprehensive assessment of patients with suspected CAD.
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity examines current data about chronic kidney disease (CKD), including its health outcomes and relationships with cardiovascular and metabolic disease. Treatment regimens aimed at delaying progression and their outcomes are reviewed, along with current knowledge regarding the pathophysiologic and genetic basis of this disease. Areas of emerging interest in research on potential new treatments targeting the causes of CKD are discussed, including genomic analysis, and their relevance to clinical care.

Pages